A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the bioequivalence of a new oxycodone formulation (80
mg) relative to the original OxyContin® (OXY) formulation (80 mg) in the fasted state.